rs10801903 (PKN2-AS1): linked to ADA and CXCL9
Upload your raw genetic data once, we'll show you which variants you carry and what the research says.
Key takeaways
- This variant is linked to higher ADA and CXCL9 levels
- The effect size for both traits is around 4.5 p less than 0.01
- PKN2 expression increases in several tissues including colon, nerve, and skin
Key takeaways This variant is linked to higher ADA and CXCL9 levels. The effect size for both traits is around 4.5 p less than 0.01. PKN2 expression increases in several tissues including colon, nerve, and skin.
What the research says This variant is associated with higher ADA and CXCL9 levels PMID 38326779. The reported effect sizes are 4.53 p=6e-6 for ADA and 4.43 p=9e-6 for CXCL9.
Reported associations
- ADA: this variant is linked to higher levels, a reported effect size of 4.53 p=6e-6 PMID 38326779
- CXCL9: this variant is linked to higher levels, a reported effect size of 4.43 p=9e-6 PMID 38326779
Evidence quality The evidence comes from a single GWAS catalog entry with 359 participants and significant p-values but limited replication [PMID 38326779].
Tissue-specific expression effects
- PKN2: increased expression in colon transverse tissue GTEx Portal
No lifestyle considerations on file for this variant.
Frequently asked questions
What does the rs10801903 variant do?
It is linked to higher levels of ADA and CXCL9 and increased expression in several tissues.
Is this SNP related to disease?
The evidence shows associations with these proteins but no direct disease link is reported.
Can I change my PKN2 level?
There are no lifestyle changes that affect this variant's effect on protein levels.